#3115
Assessing the management of bone metastases in patients diagnosed with neuroendocrine neoplasms: Re-audit of clinical practice
Introduction:
There remains no global consensus on the optimal management of bone metastases in patients with neuroendocrine neoplasms (BM-NEN).
Conference:
18th Annual ENETS Concerence (2021)
Presenting Author:
Authors:
García-Torralba E,
Lim K,
Barriuso J,
McNamara M,
Hubner R,
Keywords:
bone metastases,
neuroendocrine neoplasm,
skeletal-related events,
bisphosphonates,
radiotherapy,
guidelines,
#2903
Bone Metastases (BM) in Neuroendocrine Tumors (NET): Imaging Characteristics and Clinical Implications. A Single-Institution Experience
Introduction:
The incidence of BM in NET is underestimated and there is no consensus on clinical features, diagnostic techniques, and treatment options.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Smiroldo V
Authors:
Smiroldo V,
Lania A,
Pedicini V,
Pepe G,
Zerbi A,
Keywords:
bone metastases,
skeletal related event,
survival,
bisphosphonates,
68Ga-PET,
18FDG-PET,
CT scan,
#2891
Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid
Introduction:
The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Authors:
Armeni E,
Hayes A,
Gopaul A,
Aristidou I,
Navalkissoor S,
Keywords:
bone metastases,
NEN,
zoledronic acid,
skeletal related event,
#1912
Skeletal-Related Events (SREs) and Use of Antiresorptive Therapy (ART) in Patients with Bone Metastases of Neuroendocrine Neoplasms
Introduction:
Antiresorptive therapy (ART) with bisphosphonates or denosumab is effective in preventing skeletal-related events (SREs) in patients with bone metastases (BM). In neuroendocrine neoplasms (NEN), BM are a negative prognostic factor, however tend to be asymptomatic and SREs are considered rare. The role of ART in preventing SREs in NEN has not been investigated so far.
Conference:
14th Annual ENETSConcerence (2017)
Presenting Author:
Authors:
Apostolidis L,
Jäger D,
Winkler E,
Keywords:
NEN,
bone metastases,
antiresorptive treatment,
bisphosphonates,
denosumab,
